TDP Biotherapeutics

TDP Biotherapeutics is a preclinical-stage biotechnology company dedicated to developing transformative therapies for neurodegenerative diseases characterized by TDP-43 proteinopathy. The company focuses on the TAR DNA-binding protein 43 (TDP-43), a key pathological driver in conditions such as Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). By leveraging proprietary insights into TDP-43 biology, the company aims to restore normal protein function and prevent toxic aggregation. Their approach encompasses both small molecule and gene therapy modalities to address the underlying mechanisms of neuronal loss. TDP Biotherapeutics is positioned at the forefront of precision medicine for complex central nervous system disorders.